Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: A pharmacodynamic study

Journal of the American College of Cardiology

Volumn 60, Issue 3, 2012, Pages 193-199

  Alexopoulos, Dimitrios ^a   Galati, Anastasia ^a   Xanthopoulou, Ioanna ^a   Mavronasiou, Eleni ^a   Kassimis, George ^a   Theodoropoulos, Konstantinos C ^a   Makris, George ^a   Damelou, Anastasia ^a   Tsigkas, Grigorios ^a   Hahalis, George ^a   Davlouros, Periklis ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

pharmacology; platelet reactivity; platelets; prasugrel; ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; PRASUGREL; TICAGRELOR;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; ENZYME INHIBITION; FEMALE; HIGH ON TREATMENT THROMBOCYTE REACTIVITY; HUMAN; LOADING DRUG DOSE; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; THROMBOCYTE; THROMBOCYTE FUNCTION; TREATMENT DURATION; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADENOSINE; AGED; ANGIOPLASTY, BALLOON, CORONARY; CORONARY THROMBOSIS; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES; TICLOPIDINE;

EID: 84863680949     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.03.050     Document Type: Article

References (29)

1. F. Sofi, R. Marcucci, A.M. Gori, B. Giusti, R. Abbate, G.F. Gensini Clopidogrel non-responsiveness and risk of cardiovascular morbidity: an updated meta-analysis Thromb Haemost 103 2010 841 848
2. S.S. Brar, J. Ten Berg, R. Marcucci Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention a collaborative meta-analysis of individual participant data J Am Coll Cardiol 58 2011 1945 1954
3. G. Parodi, R. Marcucci, R. Valenti High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI JAMA 306 2011 1215 1223
4. T. Jernberg, C.D. Payne, K.J. Winters Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease Eur Heart J 27 2006 1166 1173
5. L. Wallentin, C. Varenhorst, S. James Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease Eur Heart J 29 2008 21 30
6. S.D. Wiviott, D. Trenk, A.L. Frelinger PRINCIPLE-TIMI 44 Investigators Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial Circulation 116 2007 2923 2932
7. G. Montalescot, G. Sideris, R. Cohen Prasugrel compared with high-dose clopidogrel in acute coronary syndrome The randomised, double-blind ACAPULCO study Thromb Haemost 103 2010 213 223
8. D.J. Angiolillo, J.F. Saucedo, R. Deraad SWAP Investigators Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study J Am Coll Cardiol 56 2010 1017 1023
9. D. Alexopoulos Prasugrel resistance: fact or fiction Platelets 23 2012 83 90
10. R.F. Storey, S. Husted, R.A. Harrington Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes J Am Coll Cardiol 50 2007 1852 1856
11. P.A. Gurbel, K.P. Bliden, K. Butler Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET Study Circulation 120 2009 2577 2585
12. R.F. Storey, D.J. Angiolillo, S.B. Patil Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy J Am Coll Cardiol 56 2010 1456 1462
13. S.D. Wiviott, E. Braunwald, C.H. McCabe TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
14. L. Wallentin, R.C. Becker, A. Budaj PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
15. D. Alexopoulos, G. Dimitropoulos, P. Davlouros Prasugrel overcomes high on-clopidogrel platelet reactivity post stenting more effectively than high dose (150 mg) clopidogrel: the importance of CYP2C19*2 genotyping J Am Coll Cardiol Intv 4 2011 403 410
16. D. Alexopoulos, I. Xanthopoulou, P. Davlouros Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel Am Heart J 162 2011 733 739
17. P.A. Gurbel, K.P. Bliden, K. Butler Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study Circulation 121 2010 1188 1199
18. L. Bonello, U.S. Tantry, R. Marcucci Working Group on High On-Treatment Platelet Reactivity Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
19. A.D. Michelson, A.L. Frelinger 3rd, E. Braunwald TRITON-TIMI 38 Investigators Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial Eur Heart J 30 2009 1753 1763
20. J.T. Brandt, S.L. Close, S.J. Iturria Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost 5 2007 2429 2436
21. H. Neubauer, A. Kaiser, B. Busse, A. Mugge Identification, evaluation and treatment of prasugrel low-response after coronary stent implantation - a preliminary study Thromb Res 126 2010 e389 e391
22. D.J. Angiolillo, J.J. Badimon, J.F. Saucedo A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 trial Eur Heart J 32 2011 838 846
23. L. Bonello, M. Pansieri, J. Mancini High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes J Am Coll Cardiol 58 2011 467 473
24. K.P. Bliden, U.S. Tantry, R.F. Storey The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET/OFFSET and RESPOND studies Am Heart J 162 2011 160 165
25. G. Biondi-Zoccai, M. Lotrionte, P. Agostoni Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes Int J Cardiol 150 2011 325 331
26. S. James, A. Budaj, P. Aylward Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial Circulation 122 2010 1056 1067
27. M.J. Price, D.J. Angiolillo, P.S. Teirstein Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) trial Circulation 124 2011 1132 1137
28. G. Patti, V. Pasceri, V. Vizzi Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study) Am J Cardiol 107 2011 995 1000
29. G. Campo, G. Parrinello, P. Ferraresi Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome J Am Coll Cardiol 57 2011 2474 2483